Example collocations logo

Malaria in sentence

933 examples of Malaria in a sentence

(Although there is no widely available vaccine for malaria, three countries are set to take part in a pilot immunization program starting in 2018, and some mosquito-borne diseases – such as yellow fever, Japanese encephalitis, and dengue – are vaccine-preventable.)
Last month marked the 120th anniversary of the discovery that female mosquitoes transmit malaria among humans.
Since then, malaria and other mosquito-borne diseases have been controlled and even eliminated in the developed world.
One proposal aims to protect native birds on Hawaii’s Kauai Island by using gene drives to reduce the population of a species of mosquito that carries avian malaria.
Furthermore, estimated malaria incidence has declined by 17% worldwide; malaria mortality rates have decreased by one-quarter since 2000; and reported malaria cases fell by more than half from 2000 to 2010 in 43 of 99 countries with ongoing malaria transmission.
WASHINGTON, DC – For those on the frontline of the battle against malaria, news of the development of a vaccine against the parasite is an exciting development.
In the 97 countries in which malaria is endemic, it ravages the economic productivity of those who can least afford it: poor people with limited access to treatment and care.
The global health community has long appreciated the importance of a vaccine in reducing the disease’s burden, and the World Health Organization is expected to make an announcement in November about the use of Mosquirix in countries where malaria is endemic, some 30 excruciating years after researchers at the pharmaceutical company GlaxoSmithKline (GSK) began working on the vaccine.
The approval is a significant step in the right direction for the prevention and control of malaria.
International non-governmental organizations and private foundations have collaborated with the public sector in the fight against malaria, providing funds and bringing attention to the issue.
The polio vaccine faced an uphill battle in Nigeria, and the new malaria vaccine could suffer a similar fate.
The approval of Mosquirix opens a promising new phase in the fight against malaria.
In the time it has taken to read this article, five children will have died from malaria.
Touring the Mwandama Village, I saw the potential of modern technologies – smart phones and mobile broadband, improved seed varieties, the latest in drip irrigation, modern diagnostic tests for malaria, and low-cost solar-energy grids – to advance human well-being in ways that simply were not feasible even a few years ago.
I saw a community health worker using a smart phone to manage malaria treatment within a household.
The worker used a low-cost diagnostic kit to confirm the malaria diagnosis, circumventing the need for a microscope and laboratory; a smart phone to key in the test results and receive advice from an “expert system” designed by public-health specialists; and state-of-the-art combination drug therapy to cure the illness.
Opening up Malaria ResearchLONDON – In recent years, tremendous progress has been made in the battle against malaria.
To be sure, there is still considerable work to be done, but the downward trend in new infections and deaths underscores the power of collaboration among governments (in malaria endemic and non-endemic countries alike), between commercial and non-profit organizations, and between academic science and medicine.
There is a growing recognition within the scientific community that no single organization or group has the know-how or resources to tackle malaria alone.
Reversing the tide on malaria requires us to pool resources and combine the diverse experience and expertise of scientists from different backgrounds and specialties.
In 2010, GSK, the Genomics Institute of the Novartis Research Foundation, and the St. Jude Children’s Research Hospital in Memphis, Tennessee, released into the public domain the details of more than 20,000 compounds that are active against the malaria parasite – 13,500 of which came from GSK’s proprietary compound library.
Through the “open access malaria box,” MMV provides physical access to a diverse selection of 400 commercially available compounds.
To date, the malaria box has been shared with more than 250 research groups in 30 countries around the world, and has led to the initiation of several new drug- discovery programs across a range of neglected diseases.
Three potential new treatments for malaria being developed by GSK (two in partnership with MMV) are progressing to clinical trials.
Another potential new drug being developed through a collaboration between GSK and MMV, for vivax malaria, is further along in the development process, having entered the final stages of clinical trials.
If successful, it will be the first treatment for relapsing malaria approved in more than 60 years.
Moreover, last year, regulators gave the green light to GSK’s malaria vaccine.
But while we have good reason to be encouraged by recent progress, we must not become complacent in our efforts to defeat malaria.
Each positive statistic is balanced by the stark reality that there are still around 200 million cases of malaria each year, killing nearly 500,000 people, the vast majority of whom are children under the age of five.
Marginalizing MalariaSAN FRANCISCO – Last fall, Bill and Melinda Gates sent shock waves through the global health community when they announced the audacious goal of eradicating human malaria from the face of the planet.
Back